

**Independent Auditors' Report on special purpose financial information prepared for consolidation purposes**

**B S R & Co. LLP., Chartered Accountants**

As requested in your instructions dated 21 April 2022, we have audited, for purposes of your audit of the consolidated financial statements of HealthCare Global Enterprises Limited (HCG) ('HCG' or 'Holding Company'), the accompanying special purpose financial information of HCG EKO Oncology LLP (referred to as 'Entity'), which comprise the special purpose Ind AS balance sheet as at 31 March 2022, and the special purpose Ind AS statement of profit and loss for the year then ended, and a summary of significant accounting policies (together referred to as 'financial information'). This financial information has been prepared solely to enable the Holding Company to prepare its consolidated financial statements and in accordance with the significant accounting policies followed by the HCG.

**Management's responsibility for the financial information**

Management is responsible for the preparation of this financial information in accordance with group accounting policies of the Holding Company, and for such internal control as management determines is necessary to enable the preparation of the financial information that is free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on this financial information based on our audit. We conducted our audit in accordance with Standards on Auditing issued by the Institute of Chartered Accountants of India. As requested, our audit procedures also included the additional procedures identified in your instructions. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial information is free from material misstatement. As requested by you, we planned and performed our audit using the materiality level specified in your instructions, which is different than the materiality level that we would have used had we been designing the audit to express an opinion on the financial information of the component alone.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial information in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group

**Opinion**

In our opinion, the accompanying financial information of the Entity as at 31 March 2022 and for the year then ended has been prepared, in all material respects, in accordance with the group accounting policies of the Holding Company.

**Basis of accounting**

Without modifying our opinion, we draw attention to Note 2 to the financial information, which describes the basis of accounting. The financial information has been prepared for the purpose of consolidation with HCG. As a result, the financial information may not be suitable for another purpose.



## **S G M & Associates LLP**

### **Restriction on use and distribution**

This financial information has been prepared for purposes of providing information to the Holding Company to enable it to prepare the consolidated financial statements of the group. As a result, the financial information is not a complete set of financial statements of the Entity in accordance with the group accounting policies of the Holding Company and is not intended to give a true and fair view of, in all material respects, the financial position of Entity as at and for the year ended 31 March 2022 in accordance with the group accounting policies of the Holding Company. The financial information may, therefore, not be suitable for another purpose.

This report is intended solely for B S R & Co. LLP., Chartered Accountants, and should not be used by or distributed to other parties.

**For S G M & Associates LLP**  
Chartered Accountants  
(LLP Registration No. 200058S)



A handwritten signature in blue ink, appearing to read "S Vishwamurthy", written over a horizontal line.

**S Vishwamurthy**  
Partner  
(Membership No.215675)

Bengaluru, 24 May 2022  
UDIN:

**HCG EKO Oncology LLP**

Special Purpose IND AS Balance Sheet as at 31 March 2022


(Amount in ₹, unless otherwise specifically mentioned)

Particulars	Note No.	As at	
		31-Mar-2022	31-Mar-2021
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	3	51,71,86,979	55,97,55,720
Other intangible assets	3	42,83,966	56,04,614
Right of use assets	29	8,87,79,481	10,00,77,671
Financial assets			
Other financial assets	4	69,93,607	67,69,447
Income tax assets (net)		95,92,486	22,84,718
Other non-current asset	5	87,71,510	1,60,33,164
<b>Total non-current assets</b>		<b>63,56,08,029</b>	<b>69,05,25,334</b>
<b>Current assets</b>			
Inventories	6	88,97,640	80,46,763
Financial assets			
Trade receivables	7	3,20,84,408	1,97,58,926
Cash and cash equivalents	8	64,01,321	22,63,445
Other financial assets	9	54,17,480	1,02,10,540
Loans	10	15,38,515	16,83,370
Other current assets	11	43,14,826	43,05,881
<b>Total current assets</b>		<b>5,86,54,190</b>	<b>4,62,68,925</b>
<b>Total assets</b>		<b>69,42,62,219</b>	<b>73,67,94,259</b>
<b>CAPITAL AND LIABILITIES</b>			
<b>Capital</b>	12		
Partners' capital account		10,00,000	10,00,000
Partners' current account		5,80,33,188	16,82,49,356
<b>Total capital</b>		<b>5,90,33,188</b>	<b>16,92,49,356</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Financial Liabilities			
Borrowings	13	24,87,79,781	28,02,58,549
Lease liabilities	29	10,07,82,604	10,73,60,201
Other liabilities	14	2,46,80,796	2,70,18,504
Provision	15	15,11,532	12,48,349
<b>Total non-current liabilities</b>		<b>37,57,54,713</b>	<b>41,58,85,603</b>
<b>Current liabilities</b>			
Financial liabilities			
Borrowings	16	3,13,48,876	2,30,01,033
Lease liabilities	29	89,39,697	57,24,032
Trade payables	17	15,40,80,015	8,43,76,155
Other financial liabilities	18	5,81,14,009	2,58,83,805
Other liabilities	19	62,98,702	1,21,26,218
Provision	20	6,93,019	5,48,057
<b>Total current liabilities</b>		<b>25,94,74,318</b>	<b>18,16,59,300</b>
<b>Total liabilities</b>		<b>69,42,62,219</b>	<b>73,67,94,259</b>

See accompanying notes forming part of the Special Purpose IND AS financial information

In terms of our report attached  
For S G M & Associates LLP  
Chartered Accountants

*S Vishwamurthy*  
S Vishwamurthy  
Partner



Bengaluru, May 2022

For HCG EKO ONCOLOGY LLP

*Dr. B. Ajankumar*  
Dr. B. Ajankumar  
Designated Partner

*Nand Singh Rathore*  
Nand Singh Rathore  
Designated Partner

Bengaluru, May 2022      Kolkata, May 2022


**HCG EKO Oncology LLP**


Special Purpose IND AS Statement of Profit and Loss for the year ended 31 Mar 2022  
(Amount in ₹, unless otherwise specifically mentioned)

Particulars	Note No.	For the year ended	
		31-Mar-2022	31-Mar-2021
Revenue from operations	21	25,67,01,836	19,07,03,627
Other income	22	29,05,933	29,11,441
<b>Total revenue</b>		<b>25,96,07,769</b>	<b>19,36,15,068</b>
<b>Expenses</b>			
Purchase of stock-in-trade		9,68,34,206	5,81,55,710
Changes in inventory of stock-in-trade		(8,50,877)	(86,043)
Employee benefit expenses	23	6,12,96,243	5,25,19,472
Finance cost	24	7,42,99,793	6,34,71,634
Depreciation and amortisation expense	25	6,86,66,030	6,68,23,594
Other expenses	26	20,98,77,616	18,39,50,309
<b>Total expenses</b>		<b>51,01,23,011</b>	<b>42,48,34,766</b>
<b>Loss before exceptional items and tax</b>		<b>(25,05,15,242)</b>	<b>(23,12,19,698)</b>
Exceptional items		-	-
<b>Loss before tax</b>		<b>(25,05,15,242)</b>	<b>(23,12,19,698)</b>
<b>Tax expense / (benefit):</b>			
Current tax		-	-
Deferred tax		-	-
<b>Loss for the year</b>		<b>(25,05,15,242)</b>	<b>(23,12,19,698)</b>
<b>Other comprehensive income / (losses)</b>			
Items that will not be reclassified to Statement of profit and loss		-	-
Remeasurements of the defined benefit plans		20,658	(124)
Income tax on the above		-	-
<b>Total comprehensive income for the year</b>		<b>(25,04,94,584)</b>	<b>(23,12,19,822)</b>

See accompanying notes forming part of the Special Purpose IND AS financial information


In terms of our report attached  
For S G M & Associates LLP  
Chartered Accountants


  
S Vishwamurthy  
Partner



Bengaluru, May 2022

For HCG EKO ONCOLOGY LLP

  
Dr. B S Ajithkumar  
Designated Partner

  
Nand Singh Rathore  
Designated Partner

Bengaluru, May 2022

Kolkata, May 2022

HCG EKO Oncology LLP

Notes forming part of financial statements

Note No. 3 (Amount in ₹, unless otherwise specifically mentioned)

3 Property, plant and equipment

Particulars	Gross Carrying Value			Disposals	Depreciation/Amortisation			Net Carrying Value	
	Balance as at	Additions	Balance as at		Depreciation expense for the year	Adjustments	Balance as at	Balance as at	
	1-Apr-2021		31-Mar-2022		1-Apr-2021		31-Mar-2022	31-Mar-2022	31-Mar-2021
Leasehold improvements	24,66,75,336	1,13,120	24,67,88,456	3,03,61,911	2,44,68,694	5,48,30,605	19,19,57,851	21,63,13,425	
Plant & machineries	23,29,74,660	1,37,00,676	24,66,75,336	66,22,449	2,37,39,462	3,03,67,917	21,63,13,425	22,63,52,211	
Furniture & fixtures	36,62,00,245	1,13,55,533	37,75,55,778	4,78,95,985	2,58,94,964	7,37,90,949	50,37,64,829	31,85,04,260	
Office equipment	36,37,73,346	24,86,899	36,62,00,245	2,27,48,063	2,57,47,922	4,78,95,983	31,83,04,260	34,09,65,283	
Computer	2,22,62,453	99,403	2,23,61,856	30,92,685	21,99,740	52,92,425	1,70,69,431	1,91,69,768	
Software	2,20,91,058	1,71,395	2,22,62,453	8,96,035	21,94,660	30,92,685	1,91,69,768	2,11,95,033	
	29,24,789	23,744	29,48,533	11,39,316	5,04,642	16,43,958	13,04,575	17,85,473	
	79,22,842	1,947	29,24,789	6,38,349	5,00,967	11,39,316	17,85,473	22,84,493	
	58,19,420	2,45,204	60,64,624	16,36,626	13,37,705	29,74,331	30,90,293	41,82,794	
	53,45,532	4,23,888	58,19,420	4,95,309	1,41,317	16,36,626	41,82,794	48,50,223	
	79,20,769	-	79,20,769	23,16,155	13,20,648	36,36,803	42,83,966	56,04,614	
	79,20,769	-	79,20,769	9,95,507	13,20,648	23,16,155	56,04,614	69,35,263	
<b>Total</b>	<b>65,18,03,012</b>	<b>1,18,37,004</b>	<b>66,36,40,016</b>	<b>8,64,42,678</b>	<b>5,57,26,394</b>	<b>14,21,69,071</b>	<b>52,14,70,945</b>	<b>56,53,60,334</b>	
<b>Previous Year</b>	<b>63,49,68,207</b>	<b>1,68,34,805</b>	<b>65,18,03,012</b>	<b>3,23,95,702</b>	<b>5,40,46,976</b>	<b>8,64,42,678</b>	<b>56,53,60,334</b>	<b>60,25,72,505</b>	



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

**Note No.****1 Nature of operations**

HCG EKO Oncology LLP ('HCG EKO' or 'LLP') is a Limited Liability Partnership registered under Limited Liability Partnership Act, 2008. HealthCare Global Enterprises Limited ('HCG') and EKO Diagnostic Private Limited ('EKO') are partners in LLP having capital and profit sharing ratio of 50:50 : 49:50. HCG EKO is engaged in managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. The LLP was incorporated on 15 May and has its registered office at # 8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027.

**2 Basis of preparation and Significant accounting policies**

The Special Purpose IND AS Financial Statements, comprising of Special Purpose IND AS Balance Sheet and Special Purpose IND AS Statement of Profit and Loss (together referred to as 'financial information'), of the LLP have been prepared as per the significant accounting policies provided by HCG and to the extent those accounting policies are applicable to the LLP. Refer Annexure 1 to these financial statements for significant accounting policies considered for the purpose of preparation of these financial information.

**4 Other non-current financial assets**

Particulars	31-Mar-2022	31-Mar-2021
Security deposit more than 12 months	58,77,170	55,57,762
Term deposit more than 12 months maturity	11,01,927	11,98,024
Interest accrued on long-term deposit	14,510	13,661
<b>Total</b>	<b>69,93,607</b>	<b>67,69,447</b>

**5 Other non-current assets**

Particulars	31-Mar-2022	31-Mar-2021
Capital advance	-	55,58,865
Prepaid expense	87,71,510	1,04,74,290
<b>Total</b>	<b>87,71,510</b>	<b>1,60,33,164</b>

**6 Inventories**

Particulars	31-Mar-2022	31-Mar-2021
Inventories (lower of cost and net realisable value)		
Medicines	79,20,632	75,18,305
Other consumables	9,77,008	5,28,458
<b>Total</b>	<b>88,97,640</b>	<b>80,46,763</b>

**7 Trade receivables**

Particulars	31-Mar-2022	31-Mar-2021
Unsecured, considered good	3,20,84,408	1,97,58,926
Credit impaired	1,65,35,528	1,23,94,364
Less: Provision for credit impaired	(1,65,35,528)	(1,23,94,364)
<b>Total</b>	<b>3,20,84,408</b>	<b>1,97,58,926</b>

**(a) The ageing of trade receivables as at the end of the reporting period is as follows:**

Outstanding for following period from due date of payment	As at	
	31-Mar-2022	31-Mar-2021
Not due	-	-
Less than six months	1,59,82,647	26,60,288
Six months to one year	2,50,76,911	2,42,57,981
One to two years	69,44,844	51,69,400
Two to three years	5,49,913	65,621
More than three years	65,621	-
Provision for doubtful trade receivables	(1,65,35,528)	(1,23,94,364)
<b>Total</b>	<b>3,20,84,408</b>	<b>1,97,58,926</b>

**8 Cash and cash equivalents**

Particulars	31-Mar-2022	31-Mar-2021
Cash-on-hand	9,24,305	3,87,926
Balances with banks in current accounts	54,77,016	18,75,519
<b>Total</b>	<b>64,01,321</b>	<b>22,63,445</b>



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note No.

**9 Other current financial assets**

Particulars	31-Mar-2022	31-Mar-2021
Security deposits	10,57,252	10,17,252
Unbilled revenue	34,77,325	85,22,465
Term deposit less than 12 months maturity	8,82,903	6,70,823
<b>Total</b>	<b>54,17,480</b>	<b>1,02,10,540</b>

**10 Loan**

Particulars	31-Mar-2022	31-Mar-2021
Current		
Loans and advances to employees	15,38,515	16,83,370
<b>Total</b>	<b>15,38,515</b>	<b>16,83,370</b>

**11 Other current assets**

Particulars	31-Mar-2022	31-Mar-2021
Prepaid expenses	25,89,217	20,79,116
Advance to vendor	17,44,607	13,24,568
Balance receivable from revenue authority	18,998	9,02,197
<b>Total</b>	<b>43,14,826</b>	<b>43,05,881</b>

**12 Partners' Capital Account**

Particulars	As at					
	31-Mar-2022			31-Mar-2021		
	HCG	EKO	Total	HCG	EKO	Total
<b>Fixed capital</b>						
Opening balance	5,05,000	4,95,000	10,00,000	5,05,000	4,95,000	10,00,000
<b>Closing balance</b>	<b>5,05,000</b>	<b>4,95,000</b>	<b>10,00,000</b>	<b>5,05,000</b>	<b>4,95,000</b>	<b>10,00,000</b>

**Partners' Current Account**

Particulars	As at					
	31-Mar-2022			31-Mar-2021		
	HCG	EKO	Total	HCG	EKO	Total
Opening balance	20,70,60,475	(3,88,11,119)	16,82,49,356	18,50,55,824	6,34,48,899	25,05,04,723
Add: Share of loss for the year	(12,64,99,765)	(12,39,94,819)	(25,04,94,584)	(11,67,66,010)	(11,44,53,812)	(23,12,19,822)
Add: Invested during the year	14,02,78,414	-	14,02,78,414	13,87,70,661	1,01,93,794	14,89,64,455
<b>Closing balance</b>	<b>22,08,39,124</b>	<b>(16,28,05,938)</b>	<b>5,80,33,186</b>	<b>20,70,60,475</b>	<b>(3,88,11,119)</b>	<b>16,82,49,356</b>

**13 Borrowings**

Particulars	31-Mar-2022	31-Mar-2021
<b>Secured</b>		
(i) Long-term loan from bank	24,87,79,781	28,02,58,549
<b>Total</b>	<b>24,87,79,781</b>	<b>28,02,58,549</b>

**(i) Terms of repayment and security**

	31-Mar-2022	31-Mar-2021
<b>Secured long-term from banks</b>		
Non-current portion	24,87,79,781	28,02,58,549
Amounts included under current maturities of long-term debt	3,13,48,876	2,30,01,033
Security: Exclusive charge on (i) all assets (equipment) purchased / funded through the above loan, (ii) all movable fixed assets and current assets (both present and future) of the LLP, including any refundable lease/rental deposit placed with lessor, excluding any assets which are charged exclusively to any lessor/vendor. Unconditional and irrevocable corporate guarantee and debt shortfall undertaking from the Partners in the LLP.		
Repayment terms and interest: Repayment in quarterly structured instalments with a moratorium of 3 years. Rate of interest is 1.25% spread over and above the bank's half yearly MCLR.		

**14 Other liabilities**

Particulars	31-Mar-2022	31-Mar-2021
(i) Deferred income	2,46,80,796	2,70,18,504
<b>Total</b>	<b>2,46,80,796</b>	<b>2,70,18,504</b>

(i) Note: Deferred income represents present value of exemption from payment of custom duty on import of capital goods, subject to fulfilment of certain conditions related to export of services under the Export Promotion Capital Goods (EPCG) Scheme of the Government of India. The LLP has considered the EPCG benefit availed is to compensate the import cost of the assets and classified EPCG benefit as capital grant. Such grant is recognised as income over the useful life of the capital asset.



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note

No.

<b>15</b>	<b>Provision</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Non-current provision				
	Provision for employee benefits:				
<b>28</b>	Gratuity		8,67,467	6,73,778	
	Compensated absences		6,44,065	5,74,571	
	<b>Total</b>		<b>15,11,532</b>	<b>12,48,349</b>	
<b>16</b>	<b>Borrowings</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Current				
<b>13</b>	Current maturities of long term debt		3,13,48,876	2,30,01,033	
	<b>Total</b>		<b>3,13,48,876</b>	<b>2,30,01,033</b>	
<b>17</b>	<b>Trade payables</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
(i)	Total outstanding dues of micro enterprises and small enterprises		-	-	
	Total outstanding dues of creditors other than micro enterprises and small enterprises		15,40,80,015	8,43,76,154	
	<b>Total</b>		<b>15,40,80,015</b>	<b>8,43,76,154</b>	
(i)	Note: There are no dues to Micro and Small Enterprises. The information disclosed with regard to Micro and Small Enterprises is based on information collected by the Management. This has been relied upon by the auditors.				
(b)	<b>Ageing of trade payables</b>				
	<b>Outstanding for following periods from due date of payment</b>	<b>Less one year</b>	<b>One to two years</b>	<b>Two to three years</b>	<b>More than three years</b>
	<b>Total</b>				
	<b>31-Mar-2022</b>				
	MSME				
	Others	12,43,26,465	2,35,83,143	46,46,229	15,24,179
	Unbilled dues				
	<b>31-Mar-2021</b>				
	MSME				
	Others	7,27,73,675	1,00,78,302	15,24,179	-
	Unbilled dues				
<b>18</b>	<b>Other financial liabilities</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Interest payable to holding company		4,69,28,667	1,46,14,615	
	Payable on purchase of fixed assets		17,37,069	29,77,990	
	Accrued salary benefits		94,48,273	82,91,200	
	<b>Total</b>		<b>5,81,14,009</b>	<b>2,58,83,805</b>	
<b>19</b>	<b>Other liabilities</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Statutory remittances		28,75,194	22,14,390	
	Advance received from patients		10,85,800	75,80,507	
	Deferred income		23,37,708	25,31,321	
	<b>Total</b>		<b>62,98,702</b>	<b>1,21,26,218</b>	
<b>20</b>	<b>Provision</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Current provision				
	Provision for employee benefits:				
<b>28</b>	Gratuity		1,72,487	1,74,419	
	Compensated absence		5,20,532	3,73,638	
	<b>Total</b>		<b>6,93,019</b>	<b>5,48,057</b>	
<b>21</b>	<b>Revenue from operations</b>				
	<b>Particulars</b>		<b>31-Mar-2022</b>	<b>31-Mar-2021</b>	
	Pharmacy sales		58,67,622	35,92,792	
	Medical service income		25,08,34,214	18,71,10,835	
	<b>Total</b>		<b>25,67,01,836</b>	<b>19,07,03,627</b>	





**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note

No.

22 Other income			
Particulars		31-Mar-2022	31-Mar-2021
Interest income from:			
Deposits with bank		1,16,831	1,12,756
Financial assets		3,69,260	3,42,572
Net gain on foreign currency transactions and translation		-	1,24,792
Interest on IT refund		88,521	-
Export incentive		23,31,321	23,31,321
<b>Total</b>		<b>29,05,933</b>	<b>29,11,441</b>
23 Employee benefit expenses			
Particulars		31-Mar-2022	31-Mar-2021
Salaries and wages		5,62,18,763	4,84,58,890
Contributions to provident and other funds		97,21,421	34,71,079
(a) Expense on employee stock option scheme		3,56,940	-
Staff welfare expenses		9,99,119	5,89,503
<b>Total</b>		<b>6,12,96,243</b>	<b>5,25,19,472</b>
(a) During the current year certain employees of the LLP have been granted employee stock option under the 'Employee Stock Option Scheme' [ESOP] of the HCG, one of the partner in the LLP. Expense on ESOP relates to stock options granted to employees of the LLP cross charged by HCG.			
24 Finance costs			
Particulars		31-Mar-2022	31-Mar-2021
Interest on:			
Term loan		2,53,21,500	3,06,45,090
Deferred payment obligation		-	2,06,270
Defined benefit obligation		59,343	48,376
Operating lease liability		1,24,48,855	1,25,87,647
Bank charges and other borrowing cost		13,99,233	27,46,569
Corporate guarantee charges		26,54,480	26,85,091
Interest on loan from partners		3,23,19,364	1,46,14,615
Net loss on foreign currency transactions and translation		97,018	(62,024)
<b>Total</b>		<b>7,42,99,793</b>	<b>6,34,71,634</b>
25 Depreciation and amortisation expense			
Particulars		31-Mar-2022	31-Mar-2021
Depreciation and amortisation		5,57,26,394	5,40,46,976
Amortisation of right-of-use assets		1,29,39,636	1,27,76,618
<b>Total</b>		<b>6,86,66,030</b>	<b>6,68,23,594</b>
26 Other expenses			
Particulars		31-Mar-2022	31-Mar-2021
Medical consultancy charges		4,85,70,383	3,72,55,163
Legal and professional fees		4,85,97,388	4,49,01,003
Lab charges		2,46,77,426	2,09,66,264
Power, fuel and water		1,45,90,111	1,50,61,291
Rent including lease rentals		24,63,231	20,12,054
Repairs and maintenance:			
Buildings		21,21,528	12,80,920
Machinery		2,48,79,477	2,07,08,956
Others		51,15,882	45,20,462
Insurance		7,80,462	5,17,319
Rates and taxes		37,94,503	36,60,410
Communication		8,36,503	9,50,727
Travelling and conveyance		32,53,358	40,42,468
Printing and stationery		22,67,443	18,52,727
House keeping and security		93,15,765	76,45,284
Business promotion expenses		87,38,307	1,05,38,766
Laundry expense		11,76,582	13,98,377
Payment to auditors for:			
Statutory audit		4,77,900	3,63,756
Provision for expected credit losses		56,49,700	52,94,364
Miscellaneous expenses		5,71,667	9,80,088
<b>Total</b>		<b>20,98,77,616</b>	<b>18,39,50,399</b>



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note

No.

**27 Financial instruments**

**27.01 Gearing ratio: The gearing ratio at end of the reporting period was as follows**

Particulars	31-Mar-2022	31-Mar-2021
Debt	28,01,28,657	30,32,59,582
Less: Cash and bank balances	64,01,321	22,63,445
<b>Net debt (A)</b>	<b>27,37,27,336</b>	<b>30,09,96,137</b>
Total capital (B)	5,90,33,186	16,92,49,356
Net debt to capital ratio (A/B)	4.64	1.78

**27.02 Categories of financial instruments**

Particulars	31-Mar-2022	31-Mar-2021
<b>Financial assets:</b>		
Measured at amortised cost		
Trade receivables	3,20,84,408	1,97,58,926
Cash and cash equivalents	64,01,321	22,63,445
Other financial assets	1,24,11,087	1,69,79,987
<b>Financial liabilities:</b>		
Measured at amortised cost		
Loans and borrowings	28,01,28,657	30,32,59,582
Trade payables	15,40,80,015	8,43,76,155
Other financial liabilities	5,81,14,009	2,58,83,805

**27.03 Fair value of the LLP's financial liabilities that are measured at fair value on a recurring basis**

Particulars	31-Mar-2022		31-Mar-2021	
	Carrying value	Fair value	Carrying value	Fair value
(i) Loans and borrowings	28,01,28,657	28,01,28,657	30,32,59,582	30,32,59,582
(ii) There is no material difference between carrying and fair value of financial liabilities. Hence, carrying value is considered as fair value.				

**27.04 Foreign currency exposure and sensitivity analysis**

Foreign currency exposure: The details of un-hedged foreign currency exposure are as follows.

Particulars	31-Mar-2022		31-Mar-2021	
	Forex	INR	Forex	INR
USD	-	-	2,34,202	1,74,64,077

Foreign currency sensitivity analysis: Financial instruments affected by changes in foreign exchange rates include borrowings, deferred payment obligations, etc. The LLP considers US Dollar. The impact on account of 5% appreciation / depreciation in the exchange rate of the above foreign currencies against INR is given below:

Particulars	31-Mar-2022		31-Mar-2021	
	Forex	INR	Forex	INR
Appreciation in the USD	-	-	2,45,912	1,83,37,273
Depreciation in the USD	-	-	2,22,492	1,65,90,881

Interest rate sensitivity analysis:

If interest rates had been 1% higher/lower and all other variables were held constant, the company's profit for the period ended / year ended would have impacted in the following manner:

Particulars	Impact on profit before tax for the year ended	
	31-Mar-2022	31-Mar-2021
<b>Decrease in interest rate by 1%</b>		
Increase in profit	28,01,287	(30,32,596)
<b>Increase in interest rate by 1%</b>		
Decrease in profit	(28,01,287)	(30,32,596)



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note  
No.

**Liquidity analysis for non-derivative liabilities**

The following table details the LLPs remaining contractual maturity for its non-derivative financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the LLP can be required to pay. The table include both interest and principal cash flows. To the extent that interest flows are floating rate, the undiscounted amount is derived from interest rate curves at the end of the reporting period. The contractual maturity is based on the earliest date on which the LLP may be required to pay.

Particulars	31-Mar-2022			Total	Carrying value
	< 1 year	1-3 years	> 3 years		
Borrowings	3,13,48,876	8,62,09,408	16,25,70,373	28,01,28,657	28,01,28,657
Trade payables	12,44,26,465	2,82,29,371	15,24,179	15,40,80,015	15,40,80,015
Other financial liabilities	5,81,14,009	-	-	5,81,14,009	5,81,14,009

Particulars	31-Mar-2021			Total	Carrying value
	< 1 year	1-3 years	> 3 years		
Borrowings	2,30,01,033	7,05,34,971	20,97,23,578	30,32,59,582	30,32,59,582
Trade payables	7,27,73,675	1,16,02,481	-	8,43,76,155	8,43,76,155
Other financial liabilities	2,58,83,805	-	-	2,58,83,805	2,58,83,805

**28 Employee benefit plans**

**Defined contribution plans**

The Group makes contributions to provident fund and employee state insurance schemes which are defined contribution plans, for qualifying employees. Under the schemes, the group is required to contribute a specified percentage of the payroll cost to fund the benefits. The contributions payable to these plans by the Company are at rates specified in the rules of the schemes and the Group has no obligations beyond its contributions.

Particulars	31-Mar-2022	31-Mar-2021
Contribution to Provident Fund and Employee State Insurance Scheme	32,09,943	30,53,460

**Defined benefit plan**

The Company and its Indian subsidiaries offers gratuity benefits, a defined employee benefit scheme to its employees. The said benefit plan is exposed to actuarial risks such as longevity risk and salary risk.

Longevity risk	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
Salary risk	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.
Interest risk	The fund has invested 100% of the funds in 'Schemes of insurance - conventional products' which are risk averse as whole of the risk is borne by the Insurance company.

The principal assumptions used for the purposes of the actuarial valuations were as follows:

Particulars	31-Mar-2022	31-Mar-2021
Discount rate	5.90%	6.00%
Salary escalation	5.00%	5.00%
Attrition rate	36.30%	35.60%
Retirement age [in years]	60	60
Mortality	IAI2012-14Ilt	

Amounts recognised in statement of profit and loss in respect of these defined benefit plans are as follows:

Particulars	31-Mar-2022	31-Mar-2021
Service cost		
Current service cost	2,75,876	2,12,313
Past service cost and (gain)/loss from settlements	-	-
Net interest expense	59,343	48,376
<b>Components of defined benefit costs recognised in profit or loss</b>	<b>3,35,219</b>	<b>2,60,689</b>
Remeasurement on the net defined benefit liability		
Return on plan assets [excluding amounts included in net interest expense] (excess) / Short return	-	-
Actuarial (gains) / losses arising from changes in demographic assumptions	-	-
Actuarial (gains) / losses arising from changes in financial assumptions	-	-
Actuarial (gains) / losses arising from experience adjustments	(20,658)	(124)
<b>Components of defined benefit costs recognised in other comprehensive income</b>	<b>(20,658)</b>	<b>(124)</b>
<b>Total</b>	<b>3,14,561</b>	<b>2,60,565</b>

The current service cost and the net interest expense for the year are included in the 'Employee benefits expense' line item in the statement of profit and loss. The remeasurement of the net defined benefit liability is included in other comprehensive income.



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note  
No.

The amount included in the balance sheet arising from the entity's obligation in respect of its defined benefit plans is as follows:

Particulars	31-Mar-2022	31-Mar-2021
Present value of funded defined benefit obligation	10,30,041	8,48,197
Fair value of plan assets	-	-
<b>Funded status</b>	<b>10,30,041</b>	<b>8,48,197</b>
Restrictions on asset recognised	-	-
<b>Net liability arising from defined benefit obligation</b>	<b>10,30,041</b>	<b>8,48,197</b>
Current	1,72,487	1,74,419
Non-current	8,57,554	6,73,778

Movements in the present value of the defined benefit obligation are as follows:

Particulars	31-Mar-2022	31-Mar-2021
Opening defined benefit obligation	8,48,197	6,40,940
Add/(Less) on account of acquisitions /business transfers	-	-
<b>Expenses recognised in the statement of profit and loss</b>		
Current service cost	2,75,876	2,12,313
Interest cost	59,343	48,376
<b>Remeasurement (gains)/losses recognised in other comprehensive income</b>		
Actuarial gains and losses arising from changes in demographic assumptions	-	-
Actuarial gains and losses arising from changes in financial assumptions	-	-
Actuarial gains and losses arising from experience adjustments	(20,658)	(124)
Acquisition / Divestiture	-	-
Benefits paid	(1,32,717)	(53,308)
<b>Closing defined benefit obligation</b>	<b>10,30,041</b>	<b>8,48,197</b>

Significant actuarial assumptions for the determination of the defined obligation are discount rate and expected salary increase. The sensitivity analysis below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

Particulars	31-Mar-2022	31-Mar-2021
If the discount rate increases 1%	31,000	27,000
If the discount rate decreases 1%	(33,000)	(29,000)

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

Furthermore, in presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet.

Expected future cash outflows towards the plan are as follows:

Particulars	31-Mar-2022	31-Mar-2021
Year 1	1,72,487	1,74,419
Year 2 to 5	7,82,000	5,75,000
Year 6 to 10	2,62,000	2,41,000
More than 10 years	40,000	39,000

**29 Disclosures in respect of operating leases**

Company as a lessee : The Company has lease contracts for their hospital and corporate. The Company's obligations under its leases are secured by the lessor's title to the leased assets.

**Amount recognised in the balance sheet**

**29.01 Right-of-use assets**

Particulars	31-Mar-2022	31-Mar-2021
Opening balance	10,93,40,883	-
Additions	-	12,56,30,907
Deletions	-	-
Amortisation for the year		
Capitalised	-	(35,13,406)
Expensed	(1,29,39,636)	(1,27,76,618)
<b>Closing balance</b>	<b>9,64,01,247</b>	<b>10,93,40,883</b>



**HCG EKO Oncology LLP**

Notes forming part of Special Purpose IND-AS financial information  
(Amount in ₹, unless otherwise specifically mentioned)

Note  
No.

<b>29.02 Lease liabilities</b>	<b>31-Mar-2022</b>	<b>31-Mar-2021</b>
<b>Particulars</b>		
Opening balance	11,98,51,588	
Addition		12,10,57,179
Accretion of interest		
Capitalised		36,41,762
Expensed	1,24,48,855	1,25,87,647
Payments	(1,62,41,500)	(1,74,35,000)
Deterioration		
<b>Closing balance</b>	<b>11,60,58,943</b>	<b>11,98,51,588</b>
Current	89,39,697	57,24,032
Non-current	10,71,19,246	11,41,27,556

**29.03 Maturity analysis, Contractual undiscounted cash flows**

<b>Particulars</b>	<b>31-Mar-2022</b>	<b>31-Mar-2021</b>
Less than one year	2,09,07,240	2,09,07,340
One to five years	15,50,79,453	12,06,87,043
More than five years	2,64,97,749	8,17,97,399
<b>Total</b>	<b>20,24,84,442</b>	<b>22,33,91,682</b>

**29.04 Amount recognised in Statement of Profit and Loss**

<b>Particulars</b>	<b>31-Mar-2022</b>	<b>31-Mar-2021</b>
(i) Other expense: Rent including lease rentals	24,63,231	20,12,054
Amortisation of right-to-use assets	1,29,39,636	1,27,76,618
Finance cost: interest on lease liabilities	1,24,48,855	1,25,87,647

(i) The Company applies the short-term lease recognition exemption to its short-term leases of certain premises taken on lease (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option)

30 Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure

